Join
Live feed
·
PRReleasevia Quantisnow
Johnson & Johnson logo

Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

ByQuantisnow·Wall Street's wire, on your screen.
JNJ· Johnson & Johnson
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track JNJ (Johnson & Johnson) and more on Quantisnow.